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Abstract
Background This is a report of an IRB-approved pilot
study of 13 patients who received a trans-oral anterior
partial fundoplication for the treatment of GERD using an
ultrasound-guided, flexible surgical stapler. All patients
had a history of PPI use, objective evidence of GERD, and
no significant comorbidity. Under general anesthesia, a
flexible stapler was passed trans-orally into the stomach
and placed two or three quintuplets of titanium staples
approximately 3 cm above the gastroesophageal junction.
The stapler contains an ultrasonic range finder, video
camera, and illuminator.
Methods Primary follow-up at 6 weeks included pH
metrics, GERD-HRQL scores, and PPI use. The protocol
allowed annual telephone interviews for the following
5 years to collect GERD-HRQL scores, PPI use, satisfac-
tion with the procedure, and willingness to have the pro-
cedure again.
Results At 6 weeks, mean total acid exposure was sig-
nificantly reduced, and 12/13 patients reduced GERD-
HRQL scores byC50 %. Twelve of 13 patients had stopped
daily GERD medications, and nine of 13 had stopped all
GERD medications. Each year, 11 of the 13 patients could
be reached with all 13 patients having at least 4-year follow-
up. Throughout the follow-up period, GERD-HRQL scores
were normal (\10) in all but one patient. All patients would
agree to do the procedure again. The median satisfaction
score is 8 (range 6–10) on a scale of 1–10. None reported
dysphagia. At 1 year, 54 % of respondents (6/11) had
eliminated PPI use, with another 27 % (3/11) taking a re-
duced dose. Combining respondents at 4 and 5 years to
account for all patients, 54 % (7/13) had eliminated and
another 23 % (3/13) reduced PPI use C50 %.
Conclusion At 5 years, the procedure remained effective
as demonstrated by the improved quality of life and
changes in PPI use. The results remained stable after the
second year.
Keywords GORD/GERD (Gastro-oesophageal reflux
disease)  Clinical papers/trials/research 
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In this paper, we provide long-term follow-up data on a
group of 13 subjects who participated in a pilot study of a
new device (MUSETM, Medigus Ltd, Omer, Israel), which
enables a single operator to trans-orally perform anterior
fundoplication (Dor–Thal [1]) for the treatment of moder-
ate-to-severe gastroesophageal reflux disease (GERD).
There is level 1a evidence that anterior fundoplication is
as effective as a 360 fundoplication (Nissen) for symptom
control in moderate-to-severe GERD [2]. Originally, both
operations were done via a thoracotomy or a laparotomy,
but today, both are generally performed laparoscopically
with similar results [3, 4]. The new device was developed
in order to make further progress in reducing the inva-
siveness of the surgical treatment of GERD, by providing a
totally trans-oral standard anti-reflux operation.
The new method uses standard 4.8 mm ‘‘B’’ titanium
surgical staples. In the process of the development, an
ex vivo study demonstrated that a stapled anterior
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fundoplication had an anti-reflux effect similar to that of a
360 fundoplication, independent of supporting structures
[5]. In addition, the safety and histologic tissue fusion of
the stapled fundoplication was tested in survival studies on
the swine model [6].
The results of the 6-week follow-up of this pilot study
were used to support the initiation of a larger, multicenter
pivotal study, the six-month results of which were recently
published [7]. This report is the first publication of long-
term outcome data of the trans-oral device.
Patients and methods
Between March and October 2007, 15 men and women
with moderate-to-severe GERD were enrolled in the study.
All signed a detailed informed consent form (ICF). The
form was written in English, translated to the local lan-
guage (Marathi), and then translated back to English by an
independent translator for verification. The ICF allowed the
investigators or their designees to interview the patient
annually for 5 years following the procedure. The study
protocol was approved by the hospital’s institutional re-
view board (IRB).
The inclusion and exclusion criteria are listed in
Table 1. All patients were on high-dose PPI treatment,
defined as twice the standard daily dosing, with incomplete
clinical response, as measured by a well-validated ques-
tionnaire (Velanovich GERD health-related quality of
life—GERD-HRQL) [8]. All had objective measures of
GERD as indicated by 24-h acid exposure tests and
symptom correlation or esophagitis. All had a dysfunc-
tional lower esophageal high-pressure zone (LEHPZ) as
determined by manometry, and none had gastric outlet
obstruction.
Patients with significant comorbidity were excluded.
Additional exclusion criteria were grade IV esophagitis,
esophageal stricture, BMI[35, and hiatal hernia[3 cm.
The procedure was conducted under general anesthesia
in an endoscopy suite. Standard gastroscopy was per-
formed to verify that no exclusion criteria have developed
between screening and the procedure. An overtube was slid
over the gastroscope and placed into the mid-esophagus.
The stapling device was then inserted through the overtube
into the stomach under direct visualization with an inte-
grated video camera. The device was articulated to visu-
alize and select the target stapling location. As the distal tip
of the device touches the fundus, direct visualization is
replaced by ultrasound to determine the distance between
the distal tip and the staple cartridge, which is located in
the shaft of the device. When an appropriate gap is
achieved, five 4.8-mm titanium surgical staples (identical
to the standard B-shaped staples used for gastroesophageal
anastomoses) are fired simultaneously. The fundus was
stapled at two or more locations about 3 cm cephalad to the
gastroesophageal junction (GEJ), covering approximately
180 degrees of the esophagus (see Fig. 1).
Six weeks after the procedure, the patients were re-ex-
amined and underwent repeat endoscopy, ambulatory acid
exposure test, and GERD-HRQL, and were questioned
regarding adverse events, medication use, and GERD
symptoms.
Patients were subsequently interviewed annually by
phone. The structured interview consisted of repeating the
GERD-HRQL questionnaire, medication use, general well-
being, and satisfaction with the procedure.
Thirteen of the 15 enrolled patients had the full proce-
dure and are included in the efficacy results. The procedure
was abandoned in two patients prior to the placement of
staples. One patient was a 20-year-old woman with a BMI
of 18. The combined thickness of the walls of the stomach
and esophagus, as measured by ultrasound, was too thin for
safe stapling with 4.8-mm staples. A second patient was
cancelled prior to the placement of the overtube due to a
complication during the preliminary gastroscopy.
Demographic data for the treated patients are provided
in Table 2. The fundus was stapled to the esophagus with
two quintuplets in four patients and with three quintuplets
in nine patients. On gastroscopic examination immediately
after the procedure, the result was anatomically identical to
a Dor–Thal anterior fundoplication (see Fig. 2).
There was one instance of benign pneumoperitoneum,
which resolved spontaneously within 48 h. There were
three additional adverse events in this series, all unrelated
to the study device. One patient, a 65-year-old man had
urinary retention and required catheterization. One patient
was found to have a duodenal ulcer at 6 weeks. He was
tested positive for H. Pylori. After treatment, H. Pylori was
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion
criteria
Age C 18 years BMI[ 35
Objective evidence of GERD Significant
comorbidity
pH\ 4 more than 7 % of time Hiatal hernia
[3 cm
pH\ 4 between 4 and 7 % of time with[50 %
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eradicated, and the ulcer healed. Another patient developed
superficial thrombophlebitis at the site of IV line
placement.
Baseline and 6-week efficacy data are provided in
Table 3. The primary success criterion was at least 50 %
improvement in off PPI GERD-HRQL scores. At 6 weeks,
median (range) GERD-HRQL was reduced from 24
(10–38) at baseline to 5 (1–15). Twelve of 13 patients
(92 %) had improved GERD-HRQL scores by more than
50 %. The remaining subject had a post-procedure score of
15 and a baseline score of 29 (48 % reduction).
Mean total acid exposure was significantly reduced
(p\ 0.002, ranked sign test) from 16.3 to 8.6 (median 11.0
to 5.0). Seven of 13 patients (54 %) had normalized acid
exposure as defined by percent of total time pH\ 4 of 5 %
or less.
Use of daily PPI was eliminated in 12/13 patients
(92 %), with 10/13 (69 %) completely off of any PPIs. One
patient was on a reduced daily dosage, one used PPIs on
alternate days, and one claimed to use PPIs only occa-
sionally. One patient reported taking an occasional H2
receptor blocker, but no PPI.
Annual follow-up data are provided in Table 4. Each
year during the annual phone interviews, at least 11 pa-
tients could be located, but not always the same 11.
However, all 13 patients had at least 4 years of follow-up.
All patients but one had at least 50 % reduction in their
pre-procedure GERD-HRQL score on all follow-up inter-
views. The exception was the patient whose preoperative
score was 29. The score was 14 at years 2 and 4 ([50 %
Fig. 1 Trans-oral stapling procedure: Stapler positioned under direct visualization (left), Stapling placed*3 cm cephalad to GEJ (middle); each
stapling delivers a five titanium staples (right). Schematics courtesy of Medigus, Ltd
Table 2 Patient demographic data
Number of patients enrolled 15
Patients receiving procedure 13
Age, years
Median (range) 46 (23–64)
Gender 11 Male; 2 Female
Duration of GERD symptoms, years
Median (range) 2.5 (0.5–20)
BMI (range) 18–31




(right). Photograph on right
courtesy of Prof. D. Watson,
Adelaide, Australia
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reduction), and 15 at years 1, 3, and 5. This was the only
patient who reported a non-normal ([10) score at any
interview.
At 1 year, only two of 11 (18 %) patients used daily
PPI, and 54 % of respondents (6/11) had eliminated PPI
use, with another 27 % (3/11) taking a reduced dose. At
2 years post-procedure, three of 11 patients were using
daily PPI (one at the baseline dose and two at half the
baseline dose). One patient was using PPI only occasion-
ally after heavy meals. From the second year onward, no
changes in PPI usage were reported. Combining responses
at 4 and 5 years to account for all patients, 64 % (7/13) of
patients had eliminated and another 23 % (3/13) reduced
PPI use by 50 % or more.
At every follow-up interview, all patients were satisfied
with the operation, and all would have agreed to undergo it
again.
Some of the patients reported gas bloat after heavy
meals during the first month, but none reported such ex-
periences later than 6 weeks.
Discussion
Herein, we report the long-term results of the long-term
follow-up of a less invasive method for creating anterior
fundoplication.
Between the 6-week visit and the 2-year interview, there
was a small increase in the number of patients taking PPI.
However, the patients remained satisfied and free of
symptoms, whereas before the procedure, all were symp-
tomatic on their daily dosage. This observation is similar to
that observed following Nissen fundoplication. In a fre-
quently quoted study, Spechler et al. [9] found that in
10 years, [60 % of patients eventually return to PPI
treatment; however, they remain asymptomatic and satis-
fied with the results of the operation.
A procedure failure occurred in a very thin woman. The
combined thickness of the esophageal and the gastric walls
were outside the operating range of the device. An ultra-
sound transducer at the distal tip of the device allows
precise calculation of the tissue thickness, and the user
cannot staple outside of a predetermined range (too thick or
too thin). The range is based on the 4.8 mm staple di-
mensions. It is possible that using 3.8-mm staples (Auto-
sutureTM ‘‘blue’’) would have permitted safe stapling, but
the device does not support their use. Although one subject
with a BMI of 18 had a successful procedure, the instruc-
tions for use (IFU) of the marketed version of the device
count a BMI of 20 or less as a relative contraindication.
Urinary retention after general anesthesia is not un-
common in 65-year-old men with enlarged prostate, and
patients, just as was found in this case, usually respond to
catheterization and medications [10].
The duodenal ulcer discovered at the 6-week gas-
troscopy was asymptomatic. The patient was H. Pylori
positive and most likely developed the ulcer because the
procedure effectively eliminated the symptoms of GERD.
As long as the patient was on PPI drugs, he was protected
from developing a peptic ulcer. At the 2-year follow-up,
this patient went back to PPI for dyspepsia, not for reflux
symptoms. This may be indicative of re-colonization with
H. Pylori rather than failure of the procedure. While re-
infection is rare in developed environments, in developing
countries, it is quite common, particularly after the first
year and is estimated at 12 % annually [11].
Table 3 Baseline and 6-week results for GERD-HRQL and acid
exposure
Result Baseline 6 weeks
GERD-HRQL
Mean ± SD 24.2 ± 6.9 6.5
Median 24 5
Range 10–38 1–15
Acid exposure (% time pH\ 4)
Mean ± SD 16.3 ± 13.6 8.5 ± 8.6
Median 11.0 5.0
Range 4.9–49.8 1.0–27.3
Table 4 Annual follow-up Follow-up 6 weeks 1 year 2 year 3 year 4 year 5 year 4 or 5 year
n 13/13 11/13 11/13 11/13 11/13 11/13 13/13
GERD-HRQL[ 50 % 12 10 11 10 11 10 12
Daily PPI 1 2 3 3 3 3 3
[50 % reduction 2 3 3 3 3 3 3
No 10a 6 5 5 5 5 7
Dysphagia 0 0 0 0 0 0 0
Gas Bloat 0 0 0 0 0 0 0
Do again All All All All All All All
a One patient reported occasional H2 receptor blocker use
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The new trans-oral device uses standard surgical staples
instead of sutures for tissue approximation. Our findings
are in agreement with the well-known observations that
staples of this type are as effective and durable as sutures
for approximating tissues in the GI tract [12].
The second major difference between the laparoscopic
and the trans-oral approach presented here is that the latter
was not intended to treat a sliding hiatal hernia, if present,
and, for safety considerations, is limited to patients with
HH B 3 cm. Although over half the patients with GERD
have a concomitant HH, a significant number, particularly
among patients\50 years old, do not [13]. Moreover, the
need to repair small HH’s is not clear. Richardson et al.
[14] demonstrated that fundoplication, either partial or
complete, was an independent complete reflux barrier, and
failure of the crural repair 6 months after LF does not
usually result in recurrent symptoms [15].
This pilot study was a precursor to a larger multicenter
pivotal trial [7]. The pilot study used a non-commercial
version of the MUSE system. The commercial version is
similar, but has a streamlined user interface and a lighter
construction.
In this series, as well as in the subsequent larger study,
all the procedures were performed by or under supervision
of experts in advanced endoscopy or in the use of the de-
vice. Whether non-experts can achieve similar results re-
mains an open question.
Conclusion
Although the number of pilot patients was small, the long-
term pilot results point to a trend. The data suggest that
after 2 years, the results of a stapled trans-oral anterior
fundoplication with the endoscopic stapler (MUSETM,
Medigus Ltd) remain stable and are similar to those re-
ported for laparoscopic approach. Consequently, it appears
to offer a safe and effective alternative to the more invasive
laparoscopic route, but for the present, should be restricted
to physicians with proven expertise in advanced endo-
scopic methods. The long-term follow-up of larger studies,
such as the pivotal study that led to FDA clearance, is
needed to confirm these results.
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